Alan Dal Pra

TL;DR: It is suggested that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates and numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberration outperformed well-described prognostic biomarkers.

TL;DR: A new recurrent amplification of MYCL is identified and validated, which is associated with TP53 deletion and unique profiles of DNA damage and transcriptional dysregulation, and this data represents the first systematic relation of intraprostatic genomic heterogeneity to predicted clinical outcome.

TL;DR: This is the first study of cancer outcome to integrate DNA-based and microenvironment-based failure indices to predict patient outcome and identifies low-risk to high-risk patients who are most likely to fail treatment within 18 months.

TL;DR: It is suggested that metformin may represent an effective and inexpensive means to improve radiotherapy outcome with an optimal therapeutic ratio and is associated with an independent and significant decrease in early biochemical relapse rates.

TL;DR: A novel concept is posit in IDC/CA+ prostate cancer, "nimbosus" (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality, which is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia.